Related Experiment Video
Updated: Jul 2, 2026
06:28
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
Published on: November 10, 2023
Acute myeloid leukemia in the elderly.
Hervé Dombret1, Emmanuel Raffoux, Claude Gardin
1Saint-Louis Hospital, University Paris 7, Paris, France. herve.dombret@sls.ap-hop-paris.fr <herve.dombret@sls.ap-hop-paris.fr>
Seminars in Oncology
|August 12, 2008
Summary
Older adults with acute myeloid leukemia (AML) face poor outcomes with standard chemotherapy. Research is exploring targeted intensive chemotherapy and novel, less intensive treatments like hypomethylating agents and immunotherapy.
Area of Science:
- Hematology
- Geriatric Oncology
- Clinical Therapeutics
Background:
- Acute myeloid leukemia (AML) incidence rises with age.
- Standard intensive chemotherapy yields disappointing results in elderly AML patients.
- Older adults are a key population for investigating new AML therapies.
Purpose of the Study:
- To identify older AML patients who benefit from intensive chemotherapy.
- To develop and test less intensive therapeutic strategies for other elderly AML patients.
- To explore emerging alternative treatments for AML in older adults.
Main Methods:
- Defining patient subgroups for intensive chemotherapy.
- Investigating novel therapeutic agents (hypomethylating agents, HDAC inhibitors, monoclonal antibodies, cloretazine, clofarabine).
- Evaluating reduced-intensity conditioning stem cell transplantation and immunological approaches.
Main Results:
- Ongoing research focuses on stratifying older AML patients for optimal treatment.
- Promising alternative therapies are under investigation.
- Immunological approaches and modified stem cell transplantation are being explored.
Conclusions:
- Tailoring chemotherapy intensity based on patient selection is crucial for older AML patients.
- Emerging therapies offer new hope for improving outcomes in this population.
- Further research into novel agents and immunotherapies is warranted.
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:27Disorders of Leukocytes
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...